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LETTERS TO THE EDITORRegarding “The effect of postoperative myocardial
ischemia on long-term survival after vascular surgery”
We read with interest the work by The Vascular Study Group
of New England regarding the effect of postoperative myocardial
ischemia on long-term survival after vascular surgery.1 We would
like to make several observations regarding this work.
First, it is remarkable that in this database, the proportion
of patients with a postoperative myocardial infarction (PMI;
1.6%) is higher than the proportion of patients with isolated
cardiac troponin (cTn) elevation (1.3%). Owing to the effects
of anesthesia and other factors, such as widespread use of nar-
cotics for the management of postoperative pain, the vast ma-
jority of perioperative ischemic events are clinically and
electrocardiographically silent.2,3 In the PeriOperative ISchemic
Evaluation (POISE)2 trial, 65% of patients with a PMI did not
experience ischemic symptoms, and for every patient with a
symptomatic MI, there were approximately ﬁve with an isolated
cardiac biomarker elevation (cTn or creatine kinase-MB). Of in-
terest, the risk of death at 30 days was 9.7% in patients with a
symptomatic MI and 12.5% in patients with an asymptomatic
MI.2 Thus, the presence of symptoms in the context of a rise
and fall of cTn may not be as relevant in the postoperative
setting.
Second, the peak cTn value after surgery has been shown to be
prognostically important, in particular if three or more times the
upper reference limit.4 In the study by Simons et al,1 cTn values
are not provided; instead, they are dichotomized as being above
or below a normal upper limit. Such an approach is problematic
because one could erroneously conclude that all patients with an
increased cTn have a very high risk of long-term mortality when,
in reality, only a small number of patients in that group with
very high cTn (eg, three or more) may be responsible for the
poor outcomes of an otherwise low-risk group.
Third, the cTn assays and cutoff decision limits that were used
are not described. We must emphasize that cTn assays are not stan-
dardized, and the characteristics of each assay will affect the ability
to detect ischemia. In addition, how each testing laboratory
deﬁned the upper range limit is unclear, and it must be highlighted
that cTn decision cutoffs, such as the 99th percentile, may not be
uniformly used across laboratories. Future studies should also pro-
vide data on cTn changes (D) because patients may have an
increased cTn with or without the presence of change. These
fundamental aspects are increasingly important, primarily in the
setting of the expected transition to high-sensitivity cTn assays in
the near future.
Finally, it is tempting to think that prophylactic coronary
revascularization before high-risk vascular surgery may be the
best way to prevent perioperative ischemia, but we should
remember the lessons of the Coronary Artery Revascularization
(CARP) trial.5 The most recent Universal Deﬁnition of MI task
force has recognized the importance of PMI and recommended
routine monitoring of cardiac biomarkers in high-risk patients,
before and also 48 to 72 hours after major surgery.6 We believe
the time has come to shift the focus of attention from “preopera-
tive clearance” to perioperative surveillance of myocardial ischemia
with cTns.
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Reply
We appreciate Dr Sandoval’s and Dr Garcia’s interest in our
work. Their comments highlight several aspects of our study that
are important to clarify in order to interpret our ﬁndings. The
observed higher proportion of patients in our study with postop-
erative myocardial infarction than with troponin elevation is
different from the ﬁndings of the PeriOperative ISchemic Evalu-
ation (POISE)1 trial because of key methodologic differences.
Our study was conducted retrospectively, outside of a prospec-
tive clinical trial, and troponin levels were checked only at the
discretion of the provider. In contrast, the POISE trial design
required evaluation of troponin values for all patients. Therefore,
that our study identiﬁed fewer patients with isolated troponin el-
evations is not surprising, and our study likely underestimates
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elevations.
With respect to the particular levels of troponin that were
considered signiﬁcant in our study, this point deserves further clar-
iﬁcation. An acknowledged limitation of the Vascular Study Group
of New England (VSGNE) database is that speciﬁc levels of
troponin are not collected. Similarly, details relating to the assays
used and the upper reference limits used at the various institutions
that contribute data to the VSGNE are not captured. We agree
with Dr Sandoval and Dr Garcia that this information, if it had
been available, would potentially be useful in further understanding
the association between postoperative troponin elevation and long-
term survival. We believe that further study using precise troponin
value measurements that would allow for troponin threshold ana-
lyses and stratiﬁcation by relevant cut points is warranted.
Results of the Coronary Artery Revascularization Prophylaxis
(CARP)2 trial inﬂuence not only our practice but also our deci-
sion not to draw any conclusions in our study that would contra-
dict its ﬁndings. We do not suggest prophylactic coronary
revascularization as a ﬁrst-line approach to decrease postoperative
myocardial ischemia. Further studies, such as the currently
enrolling Coronary CT Angiography Vascular Events in Non-
cardiac Vascular Surgery Patients Cohort Evaluation (CTA-
VISION)3 trial, are better suited than ours to shed light on
whether there are “high-risk” anatomies that might beneﬁt
from coronary revascularization. Instead, we recommend periop-
erative medical optimization as a potential intervention, where
evidence-based guidelines are more clearly established.4
We are in complete agreement with Drs Sandoval and Garcia
that increased awareness of new consensus recommendations5 for
routine postoperative troponin testing in high-risk patients is
needed. Our ﬁnding that isolated troponin elevations after
vascular surgery are associated with reduced postoperative 5-year
survival suggests that these events deserve to be taken seriously.
Future study will more clearly reveal whether routine postopera-
tive troponin testing is a cost-effective way in which to improve
long-term clinical outcomes after vascular surgery.
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clopidogrel is unnecessary in peripheral arterial
surgery”
We read with interest the recent article by Saadeh and Sfeir1
reporting the safety of maintaining perioperative clopidogrel in
patients undergoing peripheral arterial surgery. This supplements
similar ﬁndings from our report from the Vascular Study Group
of New England (VSGNE) demonstrating that patients can safely
undergo peripheral arterial operations while taking clopidogrel
without increased incidence of serious bleeding complications,
including bleeding requiring reoperation or increased transfusion
requirement.2
Interestingly, there is persistent variation in practice surround-
ing perioperative clopidogrel management among vascular sur-
geons. Hamish et al3 reported that 43% and 55% of surgeons
would preferentially stop clopidogrel before carotid endarterec-
tomy (CEA) for symptomatic patients and asymptomatic patients,
respectively. Furthermore, these authors noted that more than 49%
of surgeons would stop clopidogrel more than 7 days before sur-
gery, irrespective of symptom status. One can infer that these
biases reﬂect the ongoing presumption that clopidogrel is associ-
ated with increased serious bleeding complications at the time of
surgery. We also determined in another VSGNE-based study of
more than 4500 patients, which demonstrated that protamine
reduced bleeding complications after CEA, that there was no evi-
dence that clopidogrel was associated with major adverse bleeding
complications.4 Reoperation for bleeding after CEA occurred in
1.0% of patients taking clopidogrel versus 1.2% in patients not tak-
ing clopidogrel (P ¼ .67). Of note, almost all patients were
receiving antiplatelet therapy at the time of surgery (73% aspirin
only, 3% clopidogrel only, 13% aspirin and clopidogrel). Accord-
ingly, we strongly support Saadeh’s and Sfeir’s conclusion that clo-
pidogrel can be safely maintained perioperatively, which is
especially important for patients with strong indications for its
use, such as those with drug-eluting coronary stents or symptom-
atic carotid disease.
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Considering that dual antiplatelet therapy with aspirin and clo-
pidogrel now is so commonly prescribed to atherosclerotic pa-
tients, vascular surgeons worldwide are still facing the issue of
the optimal perioperative treatment of these patients on a regular
